Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT03876028
- Locations
- 🇺🇸
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03877055
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT03873493
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 207746, Houston, Texas, United States
🇬🇧Oxford University Hospitals NHS Foundation Trust /ID# 211264, Oxford, Oxfordshire, United Kingdom
🇳🇱Maxima Medisch Centrum /ID# 207989, Eindhoven, Netherlands
Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eugene Nikitin
- Target Recruit Count
- 50
- Registration Number
- NCT03827603
- Locations
- 🇷🇺
Eugene Nikitin, Moscow, Russian Federation
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 59
- Registration Number
- NCT03790332
- Locations
- 🇺🇸
Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇫🇷Hôpital Robert-Debré Ap-Hp, Paris, France
🇮🇱The Edmond and Lily Safra Children's Hospital, Ramat Gan, Israel
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03770416
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Grupo Cooperativo de Hemopatías Malignas
- Target Recruit Count
- 3
- Registration Number
- NCT03755947
- Locations
- 🇲🇽
Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 454
- Registration Number
- NCT03737981
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT03734016
- Locations
- 🇺🇸
Carti Cancer Center, Little Rock, Arkansas, United States
🇺🇸David Geffen School of Medicine At UCLA, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers Boulder, Boulder, Colorado, United States
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with P53 Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 29
- Registration Number
- NCT03734198
- Locations
- 🇫🇷
Hôpital Robert Debré - Hématologie Clinique, Reims, France
🇫🇷Chu Amiens Sud, Amiens, France
🇫🇷CHU Jean Minjoz - Hématologie, Besançon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.